Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for XXXX .

@entity1 @entity632 @entity0 @entity5 @entity1600 @entity1311 @entity3
BACKGROUND: We evaluated the accuracy of @entity1600 ( @entity1600 ) in @entity1 with @entity0 who had received preoperative therapy. METHODS: A prospective clinical trial evaluated 122 @entity1 who had @entity1600 followed by axillary lymph node dissection. Thirty-two @entity1 had @entity0 and received preoperative @entity632 -based chemotherapy or @entity1311 and radiotherapy. RESULTS: A @entity1600 ( @entity1600 ) was identified in 31 (97%) of 32 @entity1 . The @entity1600 predicted the status of the axillary nodes in 30 (97%) of 31 @entity1 . Eighteen (58%) of 31 had @entity3 in the @entity1600 . Eighteen of 19 @entity1 with axillary @entity3 had a @entity5 (sensitivity, 95%; false-negative rate, 5%). Eight (44%) of 18 @entity1 with @entity3 in the @entity1600 also had @entity3 in 1 or more nonsentinel nodes. CONCLUSIONS: In this relatively small study, the accuracy of @entity1600 in @entity1 with @entity0 treated with preoperative therapy was similar to that achieved in @entity0 . If these results are confirmed in a larger cohort, it may be feasible to substitute @entity1600 for routine axillary lymph node dissection in this population. This approach could reduce the morbidity of surgical therapy while preserving the accuracy of axillary staging and maintaining regional control in this high-risk population.
